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A tandem mass spectrometry sequence database search
method for identification of O-fucosylated proteins by mass
spectrometry.
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Abstract
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Thrombospondin type 1 repeats (TSRs), small adhesive protein domains with a wide range of
functions, are usually modified with O-linked fucose, which may be extended to O-fucose-β1,3glucose. Collision-induced dissociation (CID) spectra of O-fucosylated peptides cannot be
sequenced by standard tandem mass spectrometry (MS/MS) sequence database search engines
because O-linked glycans are highly labile in the gas phase and are effectively absent from the
CID peptide fragment spectra, resulting in a large mass error. Electron transfer dissociation (ETD)
preserves O-linked glycans on peptide fragments, but only a subset of tryptic peptides with low
m/z can be reliably sequenced from ETD spectra compared to CID. Accordingly, studies to date
that have used MS to identify O-fucosylated TSRs have required manual interpretation of CID
mass spectra even when ETD was also employed. In order to facilitate high-throughput, automatic
identification of O-fucosylated peptides from CID spectra, we re-engineered the MS/MS sequence
database search engine Comet and the MS data analysis suite Trans-Proteomic Pipeline to enable
automated sequencing of peptides exhibiting the neutral losses characteristic of labile O-linked
glycans. We used our approach to re-analyze published proteomics data from Plasmodium
parasites and identified multiple glycoforms of TSR-containing proteins.
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INTRODUCTION
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Thrombospondin type 1 repeats (TSRs) are small (~60 amino acid residues) adhesive protein
domains with a wide range of functions 1. TSRs are often modified with two unique glycans,
O-linked fucose (O-Fuc) and C-linked mannose (C-Man). The motif CX2–3(S/T)CX2G is
recognized by the O-fucosyltransferase POFUT2 2 and can be modified with O-Fuc at the
serine/threonine (Ser/Thr or S/T) residue 3. This fucose can be further extended to a fucoseβ1,3-glucose disaccharide (O-Fuc-Glc) by the β1,3-glucosyltransferase B3GLCT 4–5. TSRs
also often contain WXXW and WXXC motifs that can be modified with a C-linked mannose
(C-Man) at the tryptophan (Trp or W) residues 6–7. In C. elegans, where the first Cmannosyltransferase was discovered 8, the enzyme Dpy19 only C-mannosylates the first Trp
of the WXXW motif. However, it has recently been shown that humans possess multiple
homologs of Dpy19, and that Dpy19L1 preferentially modifies the first Trp of WXXW
while Dpy19L3 preferentially modifies the Trp of WXXC 9. In TSRs, all of these motifs
often appear in tandem as [WXX]1–3CXX(S/T)CXXG, and this short sequence may be
modified with multiple combinations of C-Man, O-Fuc, and O-Fuc-Glc within the same
organism, and even on the same protein 3. The role of these TSR glycosylations is not fully
characterized, and appears to vary by protein. In experiments where POFUT2 or Dpy19 have
been deleted, certain TSR-containing proteins exhibit stability and trafficking defects, while
other TSR-containing proteins show no discernable defect from loss of glycosylation 9–10.
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Given the heterogeneity of site occupancy and function observed to date for glycosylated
TSRs, it is desirable to be able to detect and quantify TSR glycosylation in vivo. Mass
spectrometry (MS) is typically the method of choice for high-throughput detection of protein
post-translational modifications (PTMs) because a moiety covalently bound to a peptide can
be directly detected as a mass shift, and the residue to which said modification is attached
can usually be directly inferred from the MS2 fragment spectra. However, detection of Ofucosylation of TSRs by MS is hindered by the fact that these O-linked glycans are highly
labile in the gas phase 3 and are present at very low abundance or absent from the collision
induced dissociation (CID) and higher-energy collision (HCD) MS2 peptide fragment
spectra that are typically used to sequence peptides in shotgun proteomics experiments.
When the majority of fragment ions lack the glycan due to neutral loss, typical MS/MS
sequence database search programs are incapable of identifying the peptide at all because of
the large discrepancy between the precursor parent mass (with the glycan intact) and the
masses of the deglycosylated fragments in the MS2 spectrum. It has been demonstrated that
a subset of peptides modified with O-Fuc may be sequenced by MS/MS sequence database
search engines if they were fragmented with electron transfer dissociation (ETD), which
leaves the O-linked glycan intact 11–12. However, ETD tends to only produce quality
fragment spectra at lower m/z, and many of the tryptic peptides that are readily sequenced
from CID and HCD spectra cannot be sequenced using ETD 13. For these reasons, the most
common approach to identifying O-fucosylation of TSRs has been to manually interpret
CID and HCD mass spectra of peptides bearing the predicted glycosylation motifs,
elucidating the sequence of the peptide by the unmodified fragment ions, and inferring the
identity of the O-linked glycan by the mass of the neutral loss 3, 14.
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In order to facilitate automatic identification of O-Fuc and O-Fuc-Glc from typical CID and
HCD shotgun proteomics experiments, we re-engineered several open-source software tools
for proteomics data analysis in order to enable automated sequencing and annotation of
peptides exhibiting the neutral losses characteristic of gas-phase-labile PTMs. To
demonstrate the utility of our approach, we re-analyzed published proteomics data that had
previously been manually interpreted to identify O-fucosylation of TSRs in the Plasmodium
parasites P. falciparum and P. vivax. Our method validated these results with dozens of
automatically identified and annotated corroborating spectra. We were also able to use our
approach to identify the first evidence for TSR glycosylation in P. yoelii.

EXPERIMENTAL PROCEDURES
Sample preparation

Author Manuscript
Author Manuscript

A segment of P. falciparum circumsporozoite protein (CSP; PF3D7_0304600) bearing the
TSR domain was expressed in HEK293 cells and purified as described elsewhere 15. One
hundred µg of purified protein was resuspended in 100 µL of 50 mM ammonium bicarbonate
(ABC) and 5 mM tris(2-carboxyethyl)phosphine (TCEP; (ThermoFisher Bond-Breaker
Neutral pH solution) and incubated 15 min at 50 °C, then added to a Microcon YM-3 3 kDa
molecular weight cut-off filter (Amicon Bioseparations) that had been washed with ABC.
After reducing the buffer volume by centrifugation, 100 µL of 10 mM iodoacetamide (IAM)
in 50 mM ABC was added to the filter and incubated 20 min at room temperature (RT) in
darkness. The IAM was removed by centrifugation, the filter was washed once with 100 µL
of 50 mM ABC, and 2 µg of trypsin (Promega, sequencing grade) in 50 µL of 50 mM ABC
was added to the filter, mixed by vortexing 1 min at 600 RPM in a thermomixer, and
incubated overnight at 37 °C. The digested peptides were collected by centrifugation, dried
in vacuum concentrator, and reconstituted in 50 % (v/v) methanol/0.1 % (v/v) formic acid
(FA) to a nominal peptide concentration of 1 pmol/µL.
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Recombinant P. falciparum thrombospondin-related anonymous protein (TRAP;
PF3D7_1335900) was expressed in HEK293 cells and purified as described elsewhere 16.
Six µg of PfTRAP was digested with trypsin using an S-Trap Micro (Protifi) following the
manufacturer’s instruction. Briefly, to a 6 µL aliquot of a 1 µg/µL solution of purified protein
in HEPES/NaCl buffer, 0.6 µL of 0.5 M TCEP was added (final concentration 45 mm) and
incubated 5 min at 95 °C. The solution was cooled and 0.6 µL of 1 M IAM was added and
incubated 20 min at RT in darkness. Lysis buffer (5 % (w/v) sodium dodecyl sulfate (SDS)
in 50 mM ABC) was added to achieve a final volume of 25 µL, followed by 2.5 µL of 12 %
(v/v) phosphoric acid, then 165 µL of S-Trap buffer (100 mM ABC in 90 % (v/v) methanol).
The colloidal protein precipitate that formed was collected on the S-Trap by centrifugation
and washed three times with S-Trap buffer, after which 2 µg of trypsin in 20 µL of 50 mM
ABC was placed on the trap. The trap was incubated 1 h at 47 °C and the peptides were
collected by centrifugation, followed by three additional 40 µL washes of 50 mM ABC,
0.2 % (v/v) FA, and 50 % (v/v) acetonitrile (ACN). All elution steps were combined, dried
in a vacuum concentrator, and reconstituted in 5 % (v/v) ACN/1 % (v/v) trifluoroacetic acid
(TFA) to a nominal peptide concentration of 0.2 µg/µL.
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Mass spectrometry (MS) was performed on an LTQ-Velos Pro Orbitrap Elite
(ThermoFisher). The PfCSP tryptic digest was infused directly at 500 nL/min through an
empty Picofrit column (New Objective) with a 75 µm internal diameter (ID) and a 15 µm ID
fritted tip. Mass spectra, including collision-induced dissociation (CID) and higher-energy
dissociation (HCD) MSn were collected in the Orbitrap with a nominal resolution of 240,000
at 400 m/z. Spectra were acquired through the direct acquisition function in the instrument
tune window. Ten spectra were collected for each combination of normalized collision
energy (CE) and MSn and signal-averaged in XCalibur to produce the spectra presented
here. The PfTRAP tryptic digest was analyzed by nanoflow liquid chromatography (LC)-MS
using an Agilent 1100 with electronically controlled split-flow coupled to the MS. Injections
of nominally 0.16 or 0.2 µg of peptides were loaded onto a 150 µm ID fused silica trap
column made in-house with a 10 mm bed of C18 (Dr. Maisch ReproSil Pur C18 AQ, 120 Å,
3 µm) and washed with LC load buffer (2% (v/v) ACN/0.2 % (v/v) trifluoroacetic acid
(TFA)) prior to separation on a column packed in-house with a 20 cm bed of the same
stationary phase in a Picofrit column with a 75 µm ID and a 10 µm ID fritted tip. Mobile
phase A was 0.1 % (v/v) FA in H2O and mobile phase B was 0.1 % (v/v) (FA) in ACN. The
separation gradient was as follows, all at 300 nL/min: 5 % B to 35 % B in 60 min, 35 % B to
80 % B in 10 min, 5 min at 80 % B, 80 % B to 5 % B in 1 min, and 29 min at 5 % B to reequilibrate the column. For the collision energy (CE) scanning experiment, MS1 scans were
collected in the Orbitrap from 400 – 1500 m/z at a resolution of 30,000. A data-dependent
acquisition (DDA) method was employed to select the eight most abundant precursors for
CID with a normalized CE of 35 %. CID spectra were collected in the Orbitrap at a
resolution of 15,000. Monoisotopic precursor selection was enabled. Singly charged
precursors and those with unassigned charge states were excluded from selection. An
inclusion list was employed to preferentially select 1248.01 m/z and 1329.03 m/z at CEs of
0, 5, 10, 15, 20, 25, 30, and 35 %. Dynamic exclusion was not enabled. For the experiment
targeting the multiple glycoforms of the glycosite-containing peptide, the MS method was
modified such that the MS1 scans were collected over 1000 – 1500 m/z and only doubly
charged precursors were selected for fragmentation. The inclusion list is provided in Table
S1.
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The tandem mass spectrometry sequence database search engine Comet 17 was reengineered to support the analysis of precursor mass offsets by the implementation of the
“mass_offsets” parameter. Within the Comet code, this functionality is a simple extension to
the precursor mass check function where each user defined mass offset value is subtracted
from the experimental precursor mass such that peptides that are smaller than the
experimental precursor mass by the mass offset value can still be matched to the spectrum.
Multiple mass offsets can be specified within a single search. This function was first
implemented in Comet version 2015.02 rev.0.
The peptide spectrum matches (PSMs) produced by Comet were analyzed using the TransProteomics Pipeline (TPP) version 5.1.0 Syzygy18 . In this version, the TPP spectrum level
validation tool PeptideProphet was modified to accommodate PSMs obtained with the
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mass_offsets parameter enabled in Comet. Specifically, PeptideProphet has a mass
difference model that accounts for mass differences between the measured mass of the
precursor ion and the theoretical mass of the matched peptide. This model aims to increase
the probability of PSMs that have a small mass difference between the measured and
theoretical masses and decrease the probability of PSMs that have a large mass difference,
with the actual parameters of the model learned from the dataset using the EM algorithm.
Considering the mass_offsets parameter in Comet, where the PSMs can now have a possible
number of large mass offsets and still be correct, this model had to be adjusted. Given that
the mass error of PSMs coming from searched peptides at a non-zero mass offset are
expected to be off by the mass of the lost modification for every PSM and for every possible
mass offset, the mass difference model in PeptideProphet finds the correct mass difference
by considering the mass differences between the measured precursor mass and the matched
peptide mass with the appropriate mass offset to correct for the neutral loss of the labile
modification. After considering all possible mass offsets, the mass difference that is closest
to zero is used as the corrected mass difference for consideration in the mass difference
model.
Additionally, the spectrum viewing tool Lorikeet (http://uwpr.github.io/Lorikeet/), which is
incorporated into the TPP, was updated to automatically annotate features specific to Cmannosylated peptides. Upon recognizing modification of Trp residues with a mass of
162.05 (hexose), the viewer now provides the option of annotating neutral loss of 120.04
(from cross-ring cleavage of C-Man) from the precursor and putatively hexosylated
fragments.
Peak list generation
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The MS data and associated database and analysis files generated for this work are available
at www.peptidatlas.org 19 using the identifier PASS01201. The MS data from previously
reported analyses of salivary gland sporozoites 20–22 were obtained from PeptideAtlas using
the identifiers PASS00095 and PASS00729 (P. falciparum salivary gland sporozoites),
PASS00098 (P. yoelii salivary gland sporozoites), and PASS00976 (P. vivax salivary gland
sporozoites). Mass spectrometer output files were converted to mzML format using
msConvert version 3.0.6002 from the ProteoWizard toolkit 23 and searched with Comet
version 2017.01 rev.1 17. The precursor mass tolerance was set to ±10 ppm. For the
recombinant PfTRAP LC/MS data, for which the MS2 were collected at high resolution in
the Orbitrap, the fragment ions bins were set to a tolerance of 0.02 m/z, the monoisotopic
mass offset was 0.0, and the theoretical fragment ions setting was set at 0 (“use flanking
peaks”). For the sporozoite global proteome data, for which the MS2 were collected at low
resolution in the LTQ, the bin tolerance was set to 1.0005 m/z, the monoisotopic mass offset
was set to 0.4 m/z, and the theoretical fragment ions setting was 1 (“M peak only”). Semitryptic peptides and up to 2 missed cleavages were allowed. The search parameters included
a static modification of +57.021464 Da at Cys for formation of S-carboxamidomethyl-Cys
by IAM and potential modifications of +15.994915 Da at Met and Trp for oxidation,
+31.989829 Da at Trp for dioxidation, and +162.052824 Da at Trp for C-mannosylation.
The mass_offset parameter was set to allow mass offsets of 0, +146.057909, and
+308.1107321 Da for no neutral loss and neutral loss of deoxyhexose or
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hexosyldeoxyhexose, respectively. The recombinant PfTRAP spectra were searched against
a database comprising P. falciparum TRAP (PF3D7_1335900) and the common Repository
of Adventitious Proteins (v.2012.01.01, The Global Proteome Machine, www.thegpm.org/
cRAP, 116 entries). The sporozoite data were searched against P. falciparum 3D7 24
(PlasmoDB v.35, www.plasmodb.org 25, 5548 entries), P. yoelii yoelii 17X 26 (PlasmoDB v.
35, 6092 entries), or P. vivax P01 27 (PlasmoDB v.31) appended with sequence
polymorphisms observed in other field isolates 22 (6670 entries), as appropriate for the
sample. Each of these Plasmodium databases was appended with the mosquito protein
database Anopheles stephensi Indian AsteI2.3 28 (VectorBase, www.vectorbase.org 29,
11789 entries), and the cRAP proteins. For each database, decoy proteins with the residues
between tryptic residues randomly shuffled were generated using a tool included in the TPP
and interleaved among the target entries. The MS2 spectra were analyzed using the TPP
version 5.1.0 Syzygy. PSMs were assigned scores in PeptideProphet 30 using the following
options: nonparametric model (NONPARAM), use Expect value as the only contributor to
the f-score (EXPECTSCORE), accurate mass binning of high-accuracy precursor mass
(ACCMASS PPM), report results with minimum probability of zero (ZERO), identify decoy
entries in the database and use decoys to build models (DECOY=DECOY). For the
recombinant PfTRAP data, only very high-quality PSMs were counted (those identified with
a PeptideProphet probability of 1.0 and an Expect score less than 10−5). For the re-analysis
of sporozoite proteome datasets, the DECOYPROBS flag was used to assign possible nonzero probabilities to decoy entries, enabling determination of the decoy-estimated false
discovery rate (FDR) among peptides identified with mass shifts. Only PSMs identified with
a PeptideProphet probability corresponding to a model-estimated FDR less than 1.0 % were
taken for further analysis.

Author Manuscript

RESULTS AND DISCUSSION
Behavior of O-fucose and C-mannose in collision-induced dissociation.
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The TSR-containing proteins circumsporozoite protein (CSP) and thrombospondin-related
anonymous protein (TRAP) are major surface proteins of salivary gland sporozoites, the
form of the Plasmodium parasite that is transmitted from the mosquito vector to the
vertebrate host. Expressing CSP and TRAP in HEK293 cells has been shown to modify the
TSRs of these proteins with C-Man and O-Fuc-Glc 15, 31–32. We analyzed recombinant P.
falciparum CSP and TRAP by tandem mass spectrometry (MS/MS) and nano-flow liquid
chromatography (nanoLC)-MS/MS in order to characterize the behavior of O-Fuc and CMan in CID. The recombinant PfCSP was digested with trypsin and infused for direct
analysis by nanospray ionization (NSI)-MS/MS. Based on signal intensity of the parent ions,
~92% of glycosite-bearing peptide was modified with a mass equal to hexose plus
deoxyhexose ([M+2H]2+ = 1451.17 m/z), while less than 2 % was modified with a
deoxyhexose and ~7% was unmodified. The 1451.17 m/z peak was isolated and the CID
normalized collision energy (CE) was incrementally increased (Fig 1). At the CEs required
for fragmentation of the peptide backbone, the peptide underwent neutral losses producing a
dominant doubly charged ion matching the mass of the unmodified peptide ([M+2H]2+ =
1297.11 m/z) as well as lower-intensity doubly charged species matching the mass of the
peptide modified with a single deoxyhexose (i.e., fucose, [M+2H]2+ = 1370.14 m/z). MS2,
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MS3 and MS4 of these species confirmed the sequential loss of Glc and Fuc as well as the
sequence of the peptide (Fig S1). Taken together, these spectra demonstrate that the peptide
was modified with an O-linked hexosyldeoxyhexose, i.e. O-Fuc-Glc. Upon fragmentation at
a CE typical of peptide sequencing (i.e. 35%), the precursor and fragment b- and y-ions
were predominantly stripped of the labile glycan, resulting in an MS2 spectrum effectively
identifying the unmodified peptide. However, two fragment ions retaining the glycan were
detectable, enabling positive localization of the O-Fuc-Glc to the Thr residue of the
conserved O-fucosylation motif.

Author Manuscript

Recombinant PfTRAP was digested with trypsin and analyzed by nanoLC-MS/MS
employing a data-dependent analysis (DDA) approach. An inclusion list was used to target
the parent ion of the glycosite-bearing peptide modified with a mass equal to two hexoses
and a deoxyhexose ([M+2H]2+ = 1329.03 m/z). The precursor ion was fragmented at
incrementally increasing CEs as above (Fig S2). As with the recombinant PfCSP, CID
resulted in neutral loss of the O-linked glycan, revealing that the peptide was modified with
an O-linked hexosyldeoxyhexose, i.e. O-Fuc-Glc, as well as a hexose at a single Trp residue,
i.e. C-Man (Fig 2). Unlike O-linked glycans, C-Man withstands CID and is readily localized
from the dominant b- and y-ions. Furthermore, C-Man can undergo cross-ring cleavage
resulting in a neutral loss of 120.04 Da (C4H8O4) and producing diagnostic precursor and
fragment ion peaks 3. Notably, two isobaric 1329.03 m/z species were present that had
distinct LC retention times (Fig 2A), and had the C-Man attached at the first or the second
Trp residue of the WXXW motif (Fig 2B and C).
Identification of O-fucosylated proteins by automated sequence database searching
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Automated MS/MS sequence database search tools routinely identify protein PTMs by
allowing for variable modification of peptide residues with fixed masses. However, standard
automatic search approaches are unable to identify O-glycosylated peptides such as those
described above because the most intense fragment ions lack the glycan and thus do not
match the predicted fragmentation spectra. Nonetheless, based on the observation that the
MS2 spectra of such peptides can confidently identify the sequence of the unmodified
peptide, we reasoned that these peptides could be identified by a sequence database search
engine if the neutral loss of the glycan could be accounted for. To this end, we modified the
open-source MS/MS sequence database search tool Comet 17 by adding a new
“mass_offsets” parameter that allows the user to specify neutral loss masses to be variably
subtracted from precursor masses of fragment spectra. For example, in the case of the Oglucosylfucosylated PfCSP peptide described above, the parent ion had a mass of 2900.32
Da([M+2H]2+ = 1451.17 m/z). By directing Comet to variably subtract 308.11 Da (equal to
neutral loss of O-Fuc-Glc) from the precursor mass, the new predicted precursor mass of the
peptide would be 2592.21 Da ([M+2H]2+ = 1297.11 m/z), matching the mass of the peptide
identified by the unmodified peptide fragment ions in the MS2 spectrum for this species. We
re-engineered the TPP to accommodate PSMs identified using the new “mass_offset”
parameter, and we further re-engineered the automated spectral annotation tool Lorikeet to
automatically annotate neutral loss of 120 Da from cross-ring cleavage of C-man, a PTM
often found in close proximity to O-Fuc on TSRs. The data analysis workflow is
summarized in Fig 3.
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To demonstrate this modified search approach, the recombinant PfTRAP tryptic digest was
again analyzed by a DDA method, this time employing an inclusion list that targeted the
glycosite-containing peptide at multiple masses corresponding to modification with the
various combinations of two, one, or no C-Man and an O-Fuc-Glc, O-Fuc, or no O-linked
glycan. MS2 spectra were searched using Comet with allowed mass offsets of 0, 146.06, and
308.11 Da (no offset, loss of O-Fuc, and loss of O-Fuc-Glc, respectively), as well as variable
modification of +162.05 @ Trp for C-Man. The results of the Comet search were analyzed
with the TPP and peptide spectra matched with a mass offset were identified by sorting
according to the “massdiff” field in the TPP’s PepXML Viewer. This value was calculated
for each PSM as the difference between the predicted mass of the identified peptide and the
observed mass of the precursor ion (Table S2). The glycosite-containing peptide was
detected with multiple combinations of glycans (Table 1). It was imperative to cross
reference these results with the extracted ion chromatograms of the identified species, as loss
of glycans due to in-source fragmentation gave rise to spurious identifications (Fig 4). For
example, each of the two positional isoforms of the singly C-mannosylated peptide ([M
+2H]2+ = 1174.98 m/z) co-eluted with its higher-abundance, higher-mass counterpart ([M
+2H]2+ = 1329.03 m/z) which was identified with a single C-Man as well as a mass offset of
308.11 Da (O-Fuc-Glc). This observation is consistent with the 1174.98 m/z species at that
retention time arising from neutral loss of the labile O-linked glycan due to in-source CID
prior to MS2. Once properly accounted for, this in-source CID actually provided an
additional line of evidence for differentiating between C-linked and O-linked glycans that
are isobaric and otherwise indistinguishable by MS. Oxidation of tryptophan (likely
introduced artificially during sample preparation) produced additional isobaric peptide
species. For example, the peptide with a single oxidized Trp and an O-Fuc-Glc had the same
mass as the peptide modified with two C-Man modifications, but these species were easily
distinguished by MS2 and retention times (Table S2, Fig S3). The one case of
indistinguishable isobaric species was observed with the most abundant glycoform, i.e. the
peptide modified with a glucosylfucose. This glycoform was identified from the dominant
LC peak at 59.7 min, the intensity of which was more than seven-fold greater than any other
species. The glycopeptide was identified from multiple high-quality spectra, as was the coeluting peptide that had lost the disaccharide due to in-source fragmentation. Interestingly,
another co-eluting pair of peptides with identical respective masses was identified at 57.8
min. The MS2 spectra for these isobars were indistinguishable from their more abundant,
later-eluting counterparts (Fig S4). The source of this peak splitting is unclear, as no other
combination of expected glycans or oxidation states would give rise to the observed
combination of precursor mass, MS2 spectra, and co-eluting peak pairs. If the dual peaks
arose due to a chromatographic artifact or even conformational isomer of the same peptide,
similar peak pairs would not likely be detectable for the other glycoforms identified in the
sample - the minor peak intensity was only 2% of the dominant peak intensity, so additional
minor peaks arising from the other, less-abundant species would likely be below the
detection limit. While the major glycoforms were identified from multiple high-quality
PSMs, there was one incorrect identification from a sparse, low-intensity PSM that was
nonetheless assigned a high score. This PSM identified the doubly- mannosylated peptide
with neutral loss of O-Fuc, but manual inspection of the MS2 spectrum revealed that it was
actually an isobaric glycoform, the singly mannosylated peptide with neutral loss of O-Fuc-
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Glc. This correct identity could be determined from the mass of the dominant neutral loss
precursor peak as well as the fact that multiple other MS2 from the same m/z and retention
time correctly identified the singly mannosylated glycoform (Fig S5). The above examples
demonstrate that, as with any MS/MS sequence database search tool, the resulting list of
PSMs generated using our approach should always be confirmed by manual inspection of
the data, especially when considering isobaric glycoforms. However, even the many isobaric
glycoforms considered above could be confidently distinguished given sufficiently highquality spectra and chromatography.
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Because our database searching strategy is amenable to standard instrumental approaches
(i.e. untargeted DDA employing CID or HCD) and does not require identification of lowmass oxonium ions or alternative fragmentation techniques 33–34, existing mass
spectrometry data sets can be re-searched for evidence of O-fucosylation, even if the MS2
data were collected at low resolution (e.g. using an ion trap). To demonstrate this, we reanalyzed mass spectra from previously published proteomic analyses of P. falciparum, P.
vivax, and P. yoelii salivary gland sporozoites. Proteomic analyses of salivary gland
sporozoites have recently shown that the TSR domains of CSP and TRAP are glycosylated
in vivo in the human-infective Plasmodium species P. falciparum 21 and P. vivax 22.
Subsequent to those studies, it was demonstrated that the O-linked deoxyhexose observed in
P. falciparum sporozoites is, in fact, O- Fuc, and the identity of the O-fucosyltransferase was
confirmed as POFUT2 10. It has also been confirmed that P. falciparum possesses a version
of the Dpy19 C-mannosyltransferase capable of modifying the TSR domain of PfTRAP with
C-Man35. Because of the confounding effect of labile O-linked glycans on MS/MS sequence
database searching, the evidence for in vivo O-fucosylation of Plasmodium parasites in the
studies mentioned above was obtained by manually interpreting tandem mass spectra of
peptides matching the predicted mass of glycosylated peptides. Here, we have re-analyzed
those datasets with our new automated database searching approach and validated those
original findings with dozens of high-quality PSMs. Furthermore, this reanalysis provides
the first reported evidence of TSR glycosylation in the rodent-infective malaria parasite P.
yoelii.
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All data sets were acquired on an LTQ-Orbitrap with high resolution MS1 and low resolution
MS2. The P. falciparum data, which includes a global proteome analysis 20 and a
biotinylated surface-enriched sample 21, were part of the original evidence presented for Ofucosylation of TSRs in plasmodium 21, and the P. vivax dataset subsequently demonstrated
TSR glycosylation in that species as well 22. In those analyses, select MS2 spectra from
parent ions matching predicted masses were manually annotated to provide evidence of Ofucosylation and C-mannosylation. Re-analyzing the mass spectral data with our automated
database searching approach confirmed the original findings and provided extensive
additional evidence for these modifications from the same data sets (Fig 5, Table 2, Table
S3, Fig S6-S14). Re-analyzing the P. yoelii data resulted in the first reported evidence of
glycosylation of TSRs in that species (Fig 4, Fig S12-14, Table S3). CSP and TRAP in P.
yoelii were O-fucosylated at the peptides bearing the conserved glycosites in the TSR
domain. Both CSP and TRAP were only detected with O-Fuc; no evidence was observed for
the glycosite-bearing peptides from either protein in unmodified form or modified with a
Fuc-Hex disaccharide (Fig S12, Fig S13). Both proteins were also C-mannosylated in the P.
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yoelii sample. As in P. falciparum, 100% of the TRAP observed in the P. yoelii sample was
C-mannosylated, and always at the second Trp residue of the WXXW motif, in marked
contrast to the recombinant PfTRAP expressed in mammalian cells, which exhibited all four
possible C-Man site occupancy combinations (Table 1), and P. vivax, in which C-Man was
not observed at all on TRAP. The presence or absence and site localization of C-Man could
be made unambiguously from intact C-Man on fragment ions. The majority of CSP was Cmannosylated (~96% based on LC peak height), a modification not observed on CSP in P.
falciparum or P. vivax. This observation confirms that, at least in P. yoelii, Plasmodium
Dpy19 is capable of mannosylating the WXXC motif even in the absence of a preceding
WXXW motif35.
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For all of the Plasmodium salivary gland sporozoite datasets analyzed, the FDR calculated
by PeptideProphet generally agreed with the decoy-estimated FDR; at a probability
corresponding to a model-estimated FDR of 1% (which should equal a decoy-estimated
FDR of approximately 0.5% after excluding the known decoys, assuming half of the
incorrect answers are decoys), the decoy-estimated FDRs for the datasets ranged from
0.26 % to 0.56 %. Among the PSMs identified above this cut-off with a putative neutral loss
of 146.06 or 308.11, none were decoy proteins. However, other real protein entries were
identified that were likely false positives (Table 2, Table S3). The most common of these,
appearing in four of the five datasets, were semi-tryptic fragments of a 39-residue human
keratin peptide found in the contaminant database. The N-terminus of the fully tryptic
peptide began with the sequence GSY. The mass of Gly-Ser is 144.05 Da and the mass of
Gly-Ser-Tyr is 307.11. Combined with a mass error of two or one protons, respectively,
arising from the incorrect isotope peak being identified as the monoisotopic peak of the
precursor peptide ion, these mass errors were within the matching tolerance of the allowed
neutral losses of 146.06 and 308.11 Da corresponding to O-Fuc and O-Fuc-Glc, respectively
(Fig S15). Considering only fully tryptic peptides eliminated these false positives and nearly
all others (Table 2), and further considering only the highest quality PSM (those with
PeptideProphet probabilities above 0.99 and Expect scores below 10-5) eliminated the
remaining spurious fully tryptic peptides. The above observations underscore the importance
of manual validation of results obtained from this database searching approach. In the case
of the samples analyzed here, the vast majority of PSMs identified with putative neutral loss
of an O-linked glycan were peptides containing the expected glycosylation sites, and manual
inspection of the MS2 spectra confirmed the quality of the matches.
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Taken together, these data demonstrate a marked variety in glycan site occupancy on
conserved TSR domains within and across Plasmodium species, inviting the question of
what roles these glycans play in TSR proteins and whether these roles are protein- and
species-specific. Importantly, these data also begin to suggest a recognition motif for the
Plasmodium C-mannosyltransferase. Further work will be required to confirm this motif and
whether the recognition sequence is conserved across Plasmodium species. Also of interest
is the variable detection of an additional hexose (presumably glucose) modifying O-Fuc. In
the datasets analyzed here, the large majority of CSP and TRAP in salivary gland
sporozoites of all species was O-fucosylated, but the disaccharide was only seen in P.
falciparum and only on a small percentage of the CSP and TRAP present (Fig 5). Further
work will be required to determine whether the failure to detect the disaccharide in the P.
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vivax and P. yoelii datasets is due to instrumental detection limit or the true absence of the
glycan. In other organisms this glycan extension is performed by β−1,3-glucosyltransferase
(B3GLCT). Although there is a P. falciparum gene with some sequence homology to
B3GLCT 20 (parasite-infected erythrocyte surface protein (PIESP1); PF3D7_0310400), this
function has not been verified, and the biological importance of this modification for the
parasite is unknown. Finally, it is important to note that the glycosite occupancy observed
for Plasmodium proteins in vivo differed considerably from that observed for the
recombinant proteins expressed in mammalian cells (compare Table 1 with Fig 5). The TSR
domains of both PfCSP 36 and PfTRAP37 are part of subunit malaria vaccine candidates 38.
Since glycosylation effectively changes antibody recognition epitopes 39, it is important to
be able to match the glycosylation patterns of the recombinant protein subunit to those
observed in vivo 15, 31–32, 40. The methods we have described here enable simple analysis of
TSR glycosylation using standard proteomics techniques and open-source analysis software.

Author Manuscript
Author Manuscript

In conclusion, the open-source MS/MS sequence database search tool Comet was reengineered to enable automatic detection of gas-phase labile O-linked mono- and
disaccharides. The analysis tools of the TPP were re-engineered to accommodate the new
information obtained from this search strategy, enabling assignment of probabilities and
FDRs to identified glycosylated peptides as well as visualization of the MS2 spectra,
including neutral losses from cross-ring cleavage of C-Man. We used this search strategy to
re-analyze published proteomics datasets, confirming manually annotated spectra that had
identified O-fucosylated peptides in P. falciparum and P. vivax, as well as identifying
previously unreported glycosylation in P. yoelii. While the workflow described here was
developed in order to identify a very specific type of glycosylation (i.e. O-fucosylation of
TSRs), the new “mass_offsets” parameter in Comet can be set by the user to search for any
predicted neutral loss. Combined with the support of the TPP analysis suite, this workflow
can in theory be used to detect peptides exhibiting neutral loss of any moiety that behaves in
a similar fashion to O-Fuc, e.g. O-GlcNAc. These tools will enable researchers to identify
these and other gas-phase labile PTMs using standard proteomics techniques, as well as to
re-analyze existing datasets for evidence of glycosylation that were not previously searched
for.
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ABBREVIATIONS
TSR

thrombospondin type 1 repeat

POFUT2

Protein O-Fucosyltransferase 2

B3GLCT

Beta-1,3-Glucosyltransferase
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Figure 1. Collision-induced dissociation of an O-fucosylated peptide.
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A tryptic digest of recombinant P. falciparum circumsporozoite protein (CSP) was directly
infused and analyzed by NSI-MS/MS. The precursor parent ion with [M+2H]2+ = 1451.17
m/z, corresponding to the mass of the potentially glycosylated peptide plus a hexose and a
deoxyhexose, was fragmented by collision-induced dissociation (CID) at multiple
normalized collision energies (CE). (A) At CE = 22%, the precursor ion was mostly intact,
but small doubly charged peaks (detail at right) were detectable at 1370.14 m/z and 1297.11
m/z, corresponding to neutral loss of hexose (i.e. glucose) and hexose plus deoxyhexose (i.e.
glucosylfucose), respectively. (B) Just a slight increase in collision energy to CE = 23 % was
sufficient to fragment most of the parent precursor ion. The dominant species was the
1297.11 m/z peak resulting from neutral loss of the O-linked disaccharide. Peptide fragment
ions could be detected at very low levels (detail at right). Red triangles are O-Fuc, blue
circles are Glc bound to O-Fuc by a β-1,3 linkage, neutral loss of water from fragment ions
is indicated with “o”, and neutral loss of O-Fuc-Glc is indicated with “*”. Most fragment
ions were missing the O-linked glycan. However, y13 and y14 peaks retaining the O-Fuc-Glc
were detected, positively localizing the O-linked glycan to the expected Thr residue. The y13
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and y14 fragments produced the highest abundance fragment ion peaks in CID spectrum of
the unglycosylated peptide (Figure S1), a common feature of y-ions with N-terminal Pro
residues. (C) At CE = 35 % the parent precursor was completely fragmented and the relative
abundance of the peptide fragment ions had increased approximately four-fold, but the
spectrum was still dominated by the intact peptide stripped of the glycan.
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Figure 2. Collision-induced dissociation of a C-mannosylated and O-fucosylated peptide.
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A tryptic digest of recombinant P. falciparum thrombospondin-related anonymous protein
(TRAP) was analyzed by LC-MS/MS. A targeted method was used that isolated the 1329.03
m/z precursor ion matching the mass of the potentially glycosylated peptide plus two
hexoses and a deoxyhexose. (A) Two isobaric glycoforms of the peptide, each a positional
isomer of the singly C-mannosylated peptide, exhibited distinct LC retention times. (B&C)
Representative MS2 spectra identifying the isoforms. Green circles are C-Man, green halfcircles are C-Man with neutral loss of 120.04 Da due to cross-ring cleavage, red triangles are
O-Fuc, blue circles are Glc bound to O-Fuc by a β-1,3 linkage. Neutral loss of water from
fragment ions is indicated with “o”, and neutral loss of O-Fuc-Glc is indicated with “*”. At
the normalized collision energy employed (CE = 35 %), the parent precursor ion was
completely fragmented, but the dominant peak matched that of the peptide after neutral loss
of a hexose and a deoxyhexose, i.e. O-Fuc-Glc. No fragment ions retained the O-linked
glycan, but the attachment site is known to be the C-terminal Thr residue in the conserved
TSR motif. The remaining hexose withstood CID and could be localized to either one of the
two Trp residues, consistent with C-Man. This identification and localization were further
corroborated by neutral loss of 120.04 Da from cross-ring cleavage of C-Man.
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Figure 3.

Summary of the data analysis workflow used to identify putatively O-fucosylated peptides
via an automated sequence database search engine.
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Figure 4. Automated identification of multiple glycoforms of recombinant PfTRAP.
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A tryptic digest of recombinant P. falciparum TRAP was analyzed by LC-MS/MS. A
targeted method was used that preferentially selected masses corresponding to the
potentially glycosylated peptide modified with the various combinations of two, one, or no
C-Man modifications and an O-Fuc-Glc, O-Fuc, or no O-linked glycan. The glycoforms
were identified using our automated database searching approach (See summary of results in
Table 1). (A) Extracted ion chromatograms of the targeted m/z values (all are [M+2H]2+).
Traces are offset for clarity. The peptide sequence is shown with the potential Cmannosylation and O-fucosylation sites underlined. Peaks are labeled with the identified
glycoform according to the inset legend. For the major species, evidence of neutral loss of
the O-linked glycan due to in-source collision-induced dissociation prior to MS2
fragmentation could be seen as lower-intensity, co-eluting peaks. (B) A representative MS2
spectrum that has been automatically annotated by a version of the spectrum visualization
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tool Lorikeet that was re-engineered to improve annotation of C-mannosylation and Ofucosylation and is included with the Trans-Proteomics Pipeline, the free and open-source
proteomics data analysis suite used to perform the analyses described here. The difference
between the observed experimental precursor mass of 1329.0304 m/z and matched peptide
mass of 1174.9770 m/z indicates that the PSM was obtained by the database searching
program Comet allowing neutral loss of 308.11 Da (loss of O-Fuc-Glc) in the MS2. The
dominant peak (yellow M++) at 1174.98 m/z is the peptide that has lost O-Fuc-Glc but
retains C-Man. Neutral loss of 120.04 Da from cross-ring cleavage of C-Man is indicated as
“−120” and neutral loss of water is indicated as “o”. The fragment spectra positively
localized the C-mannose to the C-terminal Trp.
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Figure 5. In vivo glycosylation of Plasmodium TSR domains identified from re-analysis of
published data.
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Summarized here is the site occupancy of C-mannosylation and O-fucosylation of
thrombospondin type 1 repeat (TSR) domains in circumsporozoite protein (CSP) and
thrombospondin anonymous protein (TRAP) in Plasmodium salivary gland sporozoites as
determined by automated database searching of previously published proteomics data.
Detected glycans are indicated with triangles and circles as described in the legend. The
hexose of the Fuc-Hex disaccharide is indicated as a generic hexose because neither the
identity of the sugar nor its glycosyltransferase has been identified in Plasmodium. The
approximate relative proportion of glycoforms in the analyzed samples is given as estimated
by LC peak height (see Fig S6-13).Glycosylation of CSP and TRAP has been reported in
salivary gland sporozoites of P. falciparum (Pf) 21 and P. vivax (Pv) 22. Our re-analysis of
published data from P. yoelii (Py) salivary gland sporozoites 20 has provided the first
evidence of TSR glycosylation in that species.
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Table 1.

Glycopeptides identified from LC-MS/MS analysis of recombinant PfTRAP.
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A tryptic digest of recombinant P. falciparum TRAP expressed in mammalian cells was analyzed by LCMS/MS and the MS2 spectra were searched for evidence of O-linked fucose or glucosylfucose by our
automated database searching method.

Author Manuscript

Modified Peptide

O-linked
b
Glycan

[M+2H]2+
c
m/z

time (min)

Retention
d

Proportion
e
in sample

PSMs

TASCGVWManDEWManSPCSVTCGK

Fuc-Glc

1410.06

50.5

1.27%

9

TASCGVWDEWManSPCSVTCGK

Fuc-Glc

1329.03

54.7

11.3%

19

TASCGVWManDEWSPCSVTCGK

Fuc-Glc

1329.03

55.4

2.39%

11

TASCGVWDEWManSPCSVTCGK

Fuc

1248.01

56.1

0.09%

3

TASCGVWManDEWSPCSVTCGK

Fuc

1248.01

57.0

0.08%

1

TASCGVWDEWSPCSVTCGK

Fuc-Glc

1248.01

57.8, 59.7

78.8%

120

TASCGVWDEWSPCSVTCGK

Fuc

1166.98

61.4

4.91%

20

TASCGVWDEWSPCSVTCGK

None

1093.95

61.6

1.18%

111

a

a

f

The peptide from the TSR domain of P. falciparum TRAP containing potential glycosylation sites. The localization of C-Man was directly

detected from the MS2 fragment spectra. Any O-Fuc or O-Fuc-Glc is presumed to have been attached at the C-terminal Thr residue.

b

The identity of the O-linked glycan as inferred by the neutral loss of 146.06 Da (O-Fuc) or 308.11 Da (O-Fuc-Glc) from the parent mass upon

MS2 fragmentation.

c

The m/z of the doubly charged peptide parent ion.

d

The retention time of the peptide (see Fig 4).

e
The relative proportion of the peptide in the sample based on chromatographic peak height (see Fig 4).

Author Manuscript

f

The number of high-quality peptide spectrum matches (PSMs) identifying the peptide (see Table S2). Note that the total number of PSMs
identifying the unglycosylated peptide (1093.95 m/z) was artificially high due to neutral loss of the O-linked glycan from the highly abundant Ofucosylated, unmannosylated species prior to MS2 fragmentation.
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Table 2.

Evidence for in vivo glycosylation of CSP and TRAP.
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Previously published proteomics data from analyses of Plasmodium salivary gland sporozoites was reanalyzed using our automated database searching approach for identification of neutral loss of O-linked fucose
or glucosylfucose. Peptide spectrum matches (PSMs) in this table were identified with evidence for neutral
loss of −146.06 (equal to deoxyhexose, i.e. fucose) or −308.11 (equal to hexosyldeoxyhexose, i.e.
glucosylfucose).

PSMs

TRAP
d
PSMs

Decoy
e
PSMs

Non-Decoy
False
f
Positives

Fully Tryptic
Non-Decoy
False
g
Positives

352

259

83

0

10

1

250

171

33

0

46

0

57

54

0

0

3

1

surface-enriched 21

12

0

4

0

8

1

P. yoelii 20

26

18

7

0

1

0

Sample

Total
b
PSMs

P. vivax VK210 22
P. vivax VK247 22

a

P. falciparum

Author Manuscript

global proteome 20

P. falciparum

CSP
c

a

Sources of data are cited. VK210 and VK247 refer to different P. vivax haplotypes. No evidence for O-fucosylation of TRAP was observed in the
P. falciparum global proteome dataset because the precursor ion, though highly abundant, was never selected for fragmentation because the
instrument software was unable to assign a charge state to the isotope envelope, and the ion was accordingly excluded from monoisotopic precursor
selection. A gel fraction containing TRAP from a surface-enriched P. falciparum sample was analyzed for spectral evidence of O-fucosylation of
TRAP.

b

Total number of peptide spectrum matches (PSMs) identified with a neutral loss putatively corresponding to an O-linked glycan.

c

Total number of PSMs identifying the glycosite-containing peptide of CSP with evidence for O-fucosylation.

d

Total number of PSMs identifying the glycosites-containing peptide of TRAP with evidence for O-fucosylation.
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e
The number of PSMs identified from decoy proteins.
f
The number PSMs identifying likely incorrect non-decoy proteins.
g

The number PSMs identifying fully tryptic peptides mapping to likely incorrect non-decoy proteins.

Author Manuscript
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